Growth with Named Patient Program
How the Head of Global Market Access for an oral oncolytic was able to increase revenue potential by thinking outside the U.S.
U.S. manufacturer was launching their first product, an oral oncolytic for a rare sub-indication
Forecast in the U.S. was ~ 500 patients
Challenged to increase revenue potential for the brand
Archbow consultant recognized the opportunity for a Named Patient Program (NPP) in EU & ROW markets
Identified & vetted a vendor with EU & ROW capabilities
Established protocol to import product, sell in ex-U.S. markets, collect & report AEs consistently, and communicate with HCPs
By end of year 1, 1/3 of all product sales occurring outside of U.S.
Distribution eventually expanded to multiple markets, including EU, Asia, & South America
All NPP sales counted toward U.S. revenue (top line)
Leveraged market & HCP knowledge to ensure smooth transitions to commercial operations as product was approved in ex-U.S. markets